文献速递肿瘤 PET/CT

18F-FDG PET/MRI与PET/CT对非小细胞肺癌胸部分期前瞻性比较

Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-08-03

前瞻性纳入84例病理确诊非小细胞肺癌患者,单次注射方案下先后行18F-FDG PET/CT与PET/MRI,两名读者独立评估T、N分期。PET/MRI与PET/CT的T分期一致率97.4%(38/39)、N分期一致率98.8%(83/84),两种方法T、N分期准确率差异均无统计学意义(p>0.5)。结论认为两者对非小细胞肺癌T、N分期诊断性能相当。

要点

  • PET/MRI与PET/CT的T分期一致率为97.4%(38/39),N分期一致率为98.8%(83/84)。
  • PET/CT与PET/MRI正确判定T分期分别为92.3%和89.7%,差异无统计学意义(p>0.5)。
  • PET/CT与PET/MRI正确判定N分期分别为92.9%(78/84)和91.7%(77/84),差异无统计学意义(p>0.5)。

核心结论

  • 18F-FDG PET/MRI与18F-FDG PET/CT对非小细胞肺癌患者的T分期和N分期均显示出相当的高诊断性能。

研究设计与样本

  • 前瞻性研究,共纳入84例经组织病理学确诊的非小细胞肺癌患者(男51例、女33例,平均年龄62.5±9.1岁)。
  • 患者在同一注射方案下先行18F-FDG PET/CT,随后行18F-FDG PET/MRI。
  • 两名读者分别独立评估T分期和N分期,依据美国癌症联合委员会分期手册第七版。
  • 以组织病理学为参考标准,N分期在全部84例患者中可获得,T分期在39例患者中可获得。
  • 采用McNemar卡方检验评估分期准确率的差异,原发肿瘤SUVmax与纵向直径的相关性采用Pearson相关系数分析。

主要发现

  • T分期在18F-FDG PET/MRI与18F-FDG PET/CT间一致者为39例中的38例(97.4%)。
  • 18F-FDG PET/CT正确判定T分期者为92.3%,18F-FDG PET/MRI为89.7%。
  • N分期在83/84例(98.8%)患者中一致。
  • 18F-FDG PET/CT正确判定N分期者为78/84例(92.9%),18F-FDG PET/MRI为77/84例(91.7%)。
  • 两种方法在T分期和N分期准确率上的差异均无统计学意义(p>0.5)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the diagnostic performance of 18F-FDG PET/MRI and 18F-FDG PET/CT for primary and locoregional lymph node staging in non-small cell lung cancer (NSCLC). METHODS: In this prospective study, a total of 84 patients (51 men, 33 women, mean age 62.5 ± 9.1 years) with histopathologically confirmed NSCLC underwent 18F-FDG PET/CT followed by 18F-FDG PET/MRI in a single injection protocol. Two readers independently assessed T and N staging in separate sessions according to the seventh edition of the American Joint Committee on Cancer staging manual for 18F-FDG PET/CT and 18F-FDG PET/MRI, respectively. Histopathology as a reference standard was available for N staging in all 84 patients and for T staging in 39 patients. Differences in staging accuracy were assessed by McNemars chi2 test. The maximum standardized uptake value (SUVmax) and longitudinal diameters of primary tumors were correlated using Pearson's coefficients. RESULTS: T stage was categorized concordantly in 18F-FDG PET/MRI and 18F-FDG PET/CT in 38 of 39 (97.4%) patients. Herein, 18F-FDG PET/CT and 18F-FDG PET/MRI correctly determined the T stage in 92.3 and 89.7% of patients, respectively. N stage was categorized concordantly in 83 of 84 patients (98.8%). 18F-FDG PET/CT correctly determined the N stage in 78 of 84 patients (92.9%), while 18F-FDG PET/MRI correctly determined the N stage in 77 of 84 patients (91.7%). Differences between 18F-FDG PET/CT and 18F-FDG PET/MRI in T and N staging accuracy were not statistically significant (p > 0.5, each). Tumor size and SUVmax measurements derived from both imaging modalities exhibited excellent correlation (r = 0.963 and r = 0.901, respectively). CONCLUSION: 18F-FDG PET/MRI and 18F-FDG PET/CT show an equivalently high diagnostic performance for T and N staging in patients suffering from NSCLC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kirchner J, Sawicki LM, Nensa F, et al. Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 30074073. doi:10.1007/s00259-018-4109-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。